Search Results
Your search for Matthew Stenger matches 107 pages
Showing 1 - 50Swallowing-Related Quality of Life After Radiotherapy vs Surgery for Oropharyngeal Squamous Cell Carcinoma
In the phase II ORATOR trial reported in The Lancet Oncology, Nichols et al found a statistical but not clinically meaningful improvement in swallowing-related quality of life outcomes 1 year after treatment with radiotherapy vs transoral robotic surgery and neck dissection in patients with...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
Palbociclib Plus Cetuximab in Platinum- and Cetuximab-Resistant HPV-Unrelated Head and Neck Cancer
In a phase II study reported in The Lancet Oncology, Adkins et al found that the combination of the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib and the EGFR inhibitor cetuximab showed activity in patients with either platinum- or cetuximab-resistant human papillomavirus...
Long-Term Results of the Omission of Postoperative Radiation to the Pathologically Node-Negative Neck in Primary HNSCC
Long-term results of a single-institution phase II study reported in the Journal of Clinical Oncology by Contreras et al showed that the omission of postoperative radiation therapy to the pathologically negative (PN0) neck was associated with good outcomes among patients with primary head and neck...
Dose De-escalation in Adjuvant Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Ma et al found that aggressive radiotherapy dose de-escalation in adjuvant chemoradiotherapy for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma was associated with disease control rates comparable to...
HPV DNA and Outcomes After Primary Treatment for Oral and Oropharyngeal Squamous Cell Carcinomas
In a two-institution study reported in JAMA Oncology, Fakhry et al found that persistent detection of tumor-type human papillomavirus (HPV) DNA after primary treatment for oral and oropharyngeal squamous cell carcinomas was associated with poorer outcomes. Study Details The prospective study...
Oropharyngeal Cancer Trends in White Men
In a study reported in the Journal of Clinical Oncology, Tota et al found that there has been a reduction in the increase of oropharyngeal cancer among young white men, with a high number of cases projected among older white men in coming years. As stated by the investigators, “Human...
Doxepin or Diphenhydramine/Lidocaine/Antacid Mouthwash for Radiotherapy-Related Oral Mucositis Pain
In the phase III Alliance A221304 trial reported in JAMA, Sio et al found that doxepin mouthwash and diphenhydramine/lidocaine/antacid mouthwash reduced oral mucositis pain for the first 4 hours after administration in patients with oral mucositis pain from head and neck radiotherapy, but the...
Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Tchekmedyian et al found that the multitargeted tyrosine kinase inhibitor lenvatinib was active in progressive recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 32 evaluable patients at...
Effect of PET/CT on Surgical Planning for Head and Neck Cancer
In a study reported in the Journal of Clinical Oncology, Lowe et al found that 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (PET/CT) had a high negative predictive value in the clinically N0 neck in patients with newly diagnosed head and neck squamous cell carcinoma, with ...
Response to Induction Chemotherapy and Outcomes With Definitive Chemoradiotherapy or Surgery in Sinonasal Undifferentiated Carcinoma
In a single-center experience reported in the Journal of Clinical Oncology, Amit et al found that among patients with sinonasal undifferentiated carcinoma with a favorable response to induction chemotherapy, disease-specific survival was better in those receiving definitive concurrent...
Radiotherapy Plus Cetuximab or Cisplatin in HPV-Positive Oropharyngeal Carcinoma
In a noninferiority phase III trial (NRG Oncology RTOG 1016) reported in The Lancet, Gillison et al found that radiotherapy plus cetuximab (Erbitux) was associated with poorer overall survival vs radiotherapy plus cisplatin in patients with human papillomavirus (HPV)-positive oropharyngeal...
Pembrolizumab vs Standard of Care in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In the phase III KEYNOTE-040 trial reported in The Lancet, Cohen et al found that pembrolizumab (Keytruda) was associated with a “clinically meaningful prolongation of overall survival” vs investigator’s choice of standard therapies in patients with previously treated recurrent or ...
Radiotherapy With Cisplatin or Cetuximab in Low-Risk, HPV-Positive Oropharyngeal Cancer
In the phase III De-ESCALaTE trial reported in The Lancet, Mehanna et al found no difference in severe toxicity with cisplatin vs cetuximab (Erbitux) plus radiotherapy in low-risk human papillomavirus (HPV)-positive oropharyngeal cancer. Cetuximab was associated with poorer recurrence and survival...
Multigene Classifier Test for Thyroid Nodules With Indeterminate Cytology
In a study reported in JAMA Oncology, Steward et al found that the use of a multigene genomic classifier test (ThyroSeq v3) could reduce the need for diagnostic surgery in a substantial proportion of patients with thyroid nodules with indeterminate cytology. The blinded prospective cohort...
Durvalumab With or Without Tremelimumab in Recurrent or Metastatic HNSCC With Low/No PD-L1 Expression
In a randomized phase II trial reported in JAMA Oncology, Siu et al found that the combination of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) plus the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor tremelimumab and durvalumab alone showed evidence ...
Suicide Risk Among Head and Neck Cancer Survivors
In a study reported in Cancer, Osazuwa-Peters et al found that the mortality rate from suicide among head and neck cancer survivors was twice as high as the pooled rate in survivors of 19 other cancers considered in the study. Only the rate of suicide in pancreatic cancer survivors was higher...
Low- vs High-Dose Cisplatin Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
In an analysis of Veterans Affairs data reported in the Journal of the National Cancer Institute, Bauml et al found that weekly lower-dose cisplatin vs higher-dose cisplatin given every 3 weeks as part of concurrent definitive chemoradiotherapy may not adversely affect survival, while reducing...
ASCO Endorses CAP Guideline on HPV Testing in Head and Neck Carcinoma
As reported in the Journal of Clinical Oncology by Carole Fakhry, MD, MPH, of Johns Hopkins School of Medicine, and colleagues, ASCO has endorsed the 2018 College of American Pathologists (CAP) guideline on human papillomavirus (HPV) testing in head and neck carcinoma. The endorsement was based on...
Induction Chemotherapy Followed by Cetuximab and Radiotherapy vs Concurrent Chemoradiotherapy in Head and Neck Cancer
As reported in the Journal of Clinical Oncology by Geoffrois et al, the European phase III GORTEC (Groupe Oncologie Radiothèrapie Tête et Cou) 2007-02 trial has shown no improvement in progression-free survival with induction chemotherapy followed by cetuximab and radiotherapy (RT) vs...
Pazopanib Plus Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
As reported in The Lancet Oncology by Adkins et al, the addition of the angiogenesis inhibitor pazopanib (Votrient) to cetuximab (Erbitux) in a phase Ib and expansion cohort study showed activity in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). In the...
Adding Motolimod to Standard Chemotherapy and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
In a phase II trial (Active8) reported in JAMA Oncology, Ferris et al found that the addition of the toll-like receptor 8 (TLR8) agonist motolimod to platinum-fluorouracil plus cetuximab (Erbitux) did not improve progression-free survival among all patients with recurrent or metastatic squamous...
Addition of Concurrent Chemotherapy to EGFR Inhibitor and Radiotherapy in Locally Advanced Head and Neck Carcinoma
As reported in the Journal of Clinical Oncology by Tao et al, the phase III GORTEC (Groupe Oncologie Radiothèrapie Tête et Cou) 2007-01 trial has shown improved progression-free survival with the addition of concurrent chemotherapy to cetuximab (Erbitux) and radiotherapy (RT) in...
Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma
In an international phase II trial (Mayo Clinic Phase 2 Consortium–NCI-9742) reported in the Journal of Clinical Oncology, Ma et al found that nivolumab (Opdivo) was active in previously treated recurrent or metastatic nasopharyngeal carcinoma. Study Details In the study, 44 evaluable...
Postoperative Chemoradiotherapy vs Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck
In an Australia-New Zealand phase III trial (Trans Tasman Radiation Oncology Group 05.01) reported in the Journal of Clinical Oncology, Porceddu et al found no benefit of adding carboplatin to postoperative radiation therapy in patients with high-risk cutaneous squamous cell carcinoma of the head...
Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin in Nasopharyngeal Carcinoma
As reported in The Lancet Oncology by Tang et al, a Chinese phase III noninferiority trial has shown similar progression-free survival with nedaplatin- vs cisplatin-based chemoradiotherapy in patients with stage II to IVB nasopharyngeal carcinoma, with nedaplatin being associated with fewer severe...
Competing Causes of Death vs Primary Disease in Survivors of Head and Neck Cancer
In a study reported in JAMA Oncology, Simpson et al found that each year of survival in patients with primary head and neck cancer was associated with a 26% increased risk of death from competing causes, and that competing causes predominated after 5 years postdiagnosis. Study Details The study...
Comparison of Chemoradiation Treatment Schedules in Locally Advanced Head and Neck Cancer
In an Indian phase III trial reported in the Journal of Clinical Oncology, Noronha and colleagues found that curative-intent adjuvant chemoradiotherapy with cisplatin at 100 mg/m2 every 3 weeks produced better locoregional control than cisplatin at 30 mg/m2 every week in patients with locally...
Radioiodine Treatment of Well-Differentiated Thyroid Cancer and Hematologic Malignancy Risk
In a study reported in the Journal of Clinical Oncology, Molenaar et al found that radioiodine treatment for well-differentiated thyroid cancer was associated with an increased risk of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) compared with thyroidectomy alone. Study Details ...
Number of Metastatic Lymph Nodes and Survival in Hypopharyngeal/Laryngeal Cancer
A study using National Cancer Database data has shown that the number of metastatic nodes is a primary independent factor associated with an increased mortality risk in patients with hypopharyngeal and laryngeal cancers. The study was reported in JAMA Oncology by Ho et al. Study Details The study ...
ASCO Clinical Practice Guideline Update: Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
As reported in the Journal of Clinical Oncology by Arlene A. Forastiere, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and colleagues, ASCO has issued a clinical practice guideline update on the use of larynx-preservation strategies in the treatment of laryngeal cancer. The ...
Combination Therapy for Advanced BRAF V600–Mutant Anaplastic Thyroid Cancer
A phase II study reported by Subbiah et al in the Journal of Clinical Oncology indicates activity of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. Study Details In the study,...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Harry Quon, MD, of Johns Hopkins University School of Medicine, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline on radiation therapy for...
Pembrolizumab in PD-L1–Positive Nasopharyngeal Carcinoma
As reported by Hsu et al in the Journal of Clinical Oncology, pembrolizumab (Keytruda) has shown activity in programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic nasopharyngeal carcinoma, in a cohort of the phase Ib KEYNOTE-028 trial. Study Details In the study, 27...
Cabozantinib Salvage Therapy in Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer
A phase II study has shown that cabozantinib (Cometriq) produces responses in patients with tyrosine kinase inhibitor–refractory differentiated thyroid cancer. The findings were reported by Cabanillas et al in the Journal of Clinical Oncology. MET plays a role in vascular endothelial growth...
Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer
In a Hong Kong study reported in The New England Journal of Medicine, Chan et al found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is useful in detecting nasopharyngeal carcinoma in asymptomatic individuals. Study Details In the study, 20,174 participants underwent...
Radiotherapy Fractionation for Head and Neck Cancers
An update of the Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck (MARCH) showed that hyperfractionated radiotherapy maintained a survival advantage over conventional radiotherapy in head and neck cancers. The findings were reported in The Lancet Oncology by Lacas et al. A ...
Outcome by Age With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Brose et al, a prespecified analysis of the phase III double-blind SELECT trial of lenvatinib (Lenvima) vs placebo in radioiodine-refractory differentiated thyroid cancer showed progression-free survival benefits in both older and younger...
USPSTF Recommendation on Screening for Thyroid Cancer
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has recommended against thyroid cancer screening in asymptomatic individuals. The current USPSTF statement is an update of a 1996 USPSTF recommendation statement. The recommendation was based on task force review of evidence on...
Reduced-Dose Radiotherapy for HPV-Positive Oropharyngeal Carcinoma
A phase II trial conducted at the University of California at Davis and at Los Angeles showed good outcomes with reduced-dose radiotherapy in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. These findings were reported in The Lancet Oncology by Chen et al....
Trends in Thyroid Cancer Incidence and Mortality in the United States
In a study of Surveillance, Epidemiology, and End Results-9 (SEER-9) data reported in JAMA, Lim et al found that both thyroid cancer incidence and mortality have increased over recent decades, reflecting increases in papillary thyroid cancer incidence and mortality. These findings suggest that the...
Pembrolizumab in Platinum- and Cetuximab-Refractory Head and Neck Cancer
In the phase II KEYNOTE-055 trial, pembrolizumab (Keytruda) was found to produce durable responses in patients with platinum- and cetuximab (Erbitux)-refractory head and neck squamous cell carcinoma. Results of the trial were reported by Bauml et al in the Journal of Clinical Oncology....
Delays in Radiotherapy for Head and Neck Cancer in Insured and Indigent Populations
In a study reported in the Journal of Oncology Practice, Thomas et al found that interruption of radiotherapy for head and neck cancer was more frequent and treatment outcomes were poorer among indigent populations vs commercially or Medicare-insured populations within a single academic health...
ASCO Endorses ACS Head and Neck Cancer Survivorship Care Guideline
As reported in the Journal of Clinical Oncology by Larissa Nekhlyudov, MD, MPH, of Brigham & Women’s Hospital, Harvard Medical School, and colleagues, ASCO has endorsed the 2016 American Cancer Society (ACS) guideline on head and neck cancer survivorship care. The endorsement was based on ...
Effect of Adjuvant Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Trifiletti et al found that adjuvant chemoradiotherapy was associated with a survival benefit in patients with resected locally advanced head and neck cancer with negative surgical margins and no extracapsular ...
Adding Buparlisib to Paclitaxel in Platinum-Pretreated Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and ...
Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1–2 N1–2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma....
Addition of Adjuvant Chemotherapy to Chemoradiotherapy Achieves Best Survival Results in Locally Advanced Nasopharyngeal Carcinoma
In an individual patient-data meta-analysis reported in the Journal of Clinical Oncology, Ribassin-Majed et al in the Meta-analysis of Chemotherapy in Nasopharyngeal Collaborative Group found that the addition of adjuvant chemotherapy to chemoradiotherapy was associated with the greatest overall...
Study Finds Nivolumab Improves Survival vs Standard Therapy in Recurrent Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Ferris et al found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with recurrent platinum-refractory squamous cell carcinoma of the head and neck. Study Details In this...
Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck
In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced...
